Baseline parameters and outcome results in all patients and subgroups according to Bethesda classification of disease complexity
| ACHD group | ||||
|---|---|---|---|---|
| Parameter | All patients (n=2886) | Simple lesions (n=1223) | Moderate complexity (n=976) | Great complexity (n=687) |
| Age | 33.3 (23.6 to 44.7) | 37.8 (26.6 to 51.8) | 31.1 (22.2 to 42.5) | 30.4 (22.8 to 38.8) |
| Male gender | 1445 (50.1%) | 610 (49.9%) | 528 (54.1%) | 307 (44.7%) |
| NYHA I | 57.1% | 66.7% | 67.5% | 28.4% |
| NYHA II | 34.9% | 28.4% | 29.3% | 52.3% |
| NYHA III/IV | 8.0% | 4.9% | 3.2% | 19.3% |
| Hypoalbuminaemia (n/%) | 383 (13.3%) | 148 (12.1%) | 110 (11.3%) | 125 (18.2%) |
| ALT (U/L) | 21.0 (16.0 to 29.0) | 21.0 (16.0 to 28.0) | 21.0 (16.0 to 30.0) | 22.0 (17.0 to 30.0) |
| AST (U/L) | 27.0 (22.0 to 34.0) | 27.0 (22.0 to 33.0) | 26.0 (22.0 to 34.0) | 28.0 (23.0 to 34.0) |
| Sodium (mmol/L) | 138.0 (137.0 to 140.0) | 138.0 (137.0 to 140.0) | 138.0 (137.0 to 140.0) | 138.0 (136.0 to 139.0) |
| Creatinine (μmol/L) | 77.0 (66.0 to 90.0) | 77.0 (64.0 to 90.0) | 77.0 (66.0 to 89.0) | 79.0 (67.0 to 92.0) |
| Haemoglobin (g/dL) | 14.3 (13.1 to 15.6) | 13.8 (12.7 to 15.0) | 14.2 (13.0 to 15.3) | 16.2 (14.2 to 19.0) |
| Follow-up time | 5.7 (3.3 to 9.6) | 5.6 (3.5 to 9.1) | 5.6 (3.2 to 10.1) | 5.9 (3.2 to 10.1) |
| Deaths | 327 | 101 | 71 | 155 |
| SMR for albumin≥35 g/L | 3.37 (2.90 to 3.92) | 1.77 (1.37 to 2.29) | 3.08 (2.24 to 4.23) | 14.82 (11.78 to 18.64) |
| SMR for albumin<35 g/L | 6.80 (5.47 to 8.46) | 2.53 (1.62 to 3.95) | 5.10 (3.18 to 8.19) | 46.31 (34.54 to 62.09) |
ACHD, adult congenital heart disease; ALT, alanine transaminase; AST, aspartate transaminase; NYHA, New York Heart Association; SMR, standardised mortality ratio.